Articles tagged "HLA antibodies"

2017 American Transplant Congress
Is the Time of Appearance and Resolution of De Novo HLA-DP Donor Specific Antibodies Associated with Reduced Deleterious Effect on Lung Transplant Outcomes?
A. Zhang,¹ Y. Sun,² K. McCurry,³ M. Budev.³
¹Allogen Laboratories, Cleveland Clinic, Cleveland, OH; ²Avalon University School of Medicine, Willemstad, Netherlands Antilles; ³Transplantation Center, Cleveland Clinic, Cleveland, OH
Introduction: The impact of HLA-DP de novo donor specific antibodies (dDSA) to lung transplantation (LT) is poorly understood. This study analyzed the association of timely…
2017 American Transplant Congress
Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant.
S. Davis, J. Gralla, P. Klem, A. Wiseman, J. Cooper.
University of Colorado, Aurora, CO
Tacrolimus (TAC) has a narrow therapeutic range, with its upper bounds limited by serious toxicities while TAC minimization strategies have demonstrated immunologic risk. Monitoring the…
2017 American Transplant Congress
Determinants of Severe Interstitial Fibrosis in Kidney Allografts: Major Impact of Circulating Donor-Specific Anti-HLA Antibodies.
C. Gosset, D. Viglietti, M. Rabant, E. Pillebout, J. Taupin, D. Glotz, C. Legendre, J. Duong Van-Huyen, A. Loupy, C. Lefaucheur.
Paris Translational Research Center for Organ Transplantation, Paris, France
Interstitial fibrosis represents a major cause of kidney allograft failure. We investigated the independent contribution of circulating donor-specific anti-HLA antibodies (DSA) in the development of…
2017 American Transplant Congress
IgG Antibody Subclasses in Potential Renal Transplant Recipients with DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors.
A. Contreras, A. Casillas, L. Llorente, G. Lima, A. Arvizu, A. De Santiago, M. Vilatoba, J. Alberu, J. Arreola-Guerra.
Transplantation Departament, 1b Immunology Department, Inst Nal Ciencia Medicas y Nutricion SZ, Mexico City, Mexico
Background. In kidney transplant recipients, IgG3 and IgG4 DSA have been associated with shorter time to acute AMR and with later allograft injury (glomerulopathy &…
2017 American Transplant Congress
Development of an Anti-HLA Antibody-Producing Humanized Mouse Model.
S. Yanagawa, H. Tahara, H. Ohdan.
Hiroshima University, Hiroshima, Japan; Hiroshima University, Hiroshima, Japan; Hiroshima University, Hiroshima, Japan
Chronic antibody-mediated rejection due to anti-human leukocyte antigen (HLA) antibodies (Abs) is an important problem in organ transplantation. The spleen has been reported to be…
2017 American Transplant Congress
Predicting Immunologic Risk for Acute Rejection in Pediatric Liver Transplantation.
S. Antala, L. Bow, R. Morotti, G. Gan, D. Yanhong, U. Ekong, S. Emre.
Yale University, New Haven, CT
Background: Studies in heart, lung, kidney, & liver transplantation (LT) indicate an increased negative impact of antibodies (Ab) to HLA on allograft outcome.Aim: To describe…
2017 American Transplant Congress
Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study.
E. Ko,^1,2 J. Yu,^1,2 C. Yang,^1,2 B. Chung,^1,2 Korean Organ Transplantation Registry (KOTRY).
¹Transplantation Research Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ²Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Background This is a nationwide cohort study to investigate the impact of anti-A/B antibody or donor specific anti-HLA antibody (HLA-DSA) on the clinical outcomes in…
2017 American Transplant Congress
C3d Assay Result in Potential Transplant Recipients with HLA-DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors.
A. Contreras, A. Casillas, N. Castelan, N. Gonzalez-Tableros, M. Lopez, A. Arvizu, A. De Santiago, J. Alberu, J. Arreola-Guerra.
Transplantation Department, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico
Background: In a previous study we searched the association between the flow cytometry cross-match assay (FXM) result and the results obtained in the analysis of…
2017 American Transplant Congress
Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status.
A. Babu,^1,2,3 N. Krishnan,² D. Briggs,³ D. Mitchell,¹ S. Daga.^1,2,4
¹Warwick Medical School, University of Warwick, Coventry, United Kingdom; ²Nephrology and Transplantation, University Hospitals Coventrya and Warwickshire, Coventry, United Kingdom; ³Histocompatibility and Immunogenetics, NHS Blood and Transfusion, Birmingham, United Kingdom; ⁴Nephrology and Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Introduction. Complement dependent cytotoxicity, first described in 1969 is the only functional assay studying complement activation. C3d assay is developed recently to study complement activation…
2017 American Transplant Congress
A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.
S. Tremblay,¹ A. Shields,^1,2 R. Alloway,¹ P. Brailey,¹ A. Leino,¹ A. Lichvar,¹ B. Abu Jawdeh,¹ J. Driscoll,¹ A. Girnita,¹ E. Woodle.¹
¹U of Cincinnati, Cincinnati; ²Christ Hospital, Cincinnati
Carfilzomib (CFZ) is a 2nd generation proteasome inhibitor different form bortezomib in that it irreversibly disables 20s and 26s proteasomes.Results from the first 2 phases…